SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

This study is looking for adults aged 18 and over who have multiple myeloma that has come back, especially if they've already received certain other treatments including lenalidomide and a proteasome inhibitor. Your doctors will also need to be able to measure your multiple myeloma in your blood or urine to track how the treatment is working.

There are also reasons someone might not be able to join. For example, if your multiple myeloma is growing very rapidly from the start (primary refractory), or if you've already had a similar medicine to Isatuximab too recently or had a bad reaction to it. You also wouldn't be able to join if you've previously taken pomalidomide, which is one of the treatments given in this study. Other health conditions like serious heart problems, certain previous cancers, or active infections like Hepatitis, would also prevent you from joining.

Women who could become pregnant and men with partners who could become pregnant would need to agree to use effective birth control throughout the study.

If you decide to take part, you'll be randomly assigned to one of two groups: one receiving Isatuximab as an injection under the skin, and the other receiving it through a drip into a vein. Regardless of the group, you'll also receive Pomalidomide and Dexamethasone. You will continue these treatments in cycles, typically lasting 4 weeks each. You'll have regular hospital visits for your treatments, check-ups, and blood tests to see how you're doing and how the treatment is affecting your body. You'll continue treatment for as long as it is working for you and you're not having difficult side effects, or until your doctor advises otherwise. You’ll be taking some preventative medicines like Montelukast, Paracetamol, Diphenhydramine, and Methylprednisolone to help manage potential reactions to the study drug.